J.M.G. Larkin
The Royal Marsden NHS Foundation Trust
CancerInternal medicineUrologyOncologyStage (cooking)Adverse effectVemurafenibAxitinibAvelumabRenal cell carcinomaMelanomaImmunotherapyAdjuvantTrametinibDabrafenibCobimetinibSunitinibNivolumabPembrolizumabIpilimumabIn patientAdvanced melanomaImmune checkpoint inhibitorsOverall survivalCancer researchFamily medicineClinical trialMedicine
Publications 63
#9Benjamin Shum (The Royal Marsden NHS Foundation Trust)H-Index: 2
#1Rachel H. GilesH-Index: 59
Last. Eric JonaschH-Index: 67
view all 7 authors...
#1Scott Shepherd (The Royal Marsden NHS Foundation Trust)H-Index: 7
#3Lewis Au (Francis Crick Institute)H-Index: 9
Last. Benjamin Shum (The Royal Marsden NHS Foundation Trust)H-Index: 2
view all 20 authors...
Background: Patients with cancer are at increased risk of severe outcomes from COVID-19. Understanding the impact of SARS-CoV-2 infection and vaccination induced-immunity is an area of unmet need. Methods: CAPTURE (NCT03226886) is a prospective longitudinal cohort study of COVID-19 vaccine or SARS-CoV-2 infection-induced immunity. SARS-CoV-2 infections were confirmed by RT-PCR and ELISA. Neutralising antibody titres (NAbT) against wild-type (WT) SARS-CoV-2 and variants of concern (VOC;Alpha, Bet...
#1David F. McDermottH-Index: 96
#2J-L. LeeH-Index: 5
Last. Alexandr PoprachH-Index: 17
view all 20 authors...
#1Toni K. Choueiri (Brigham and Women's Hospital)H-Index: 120
#2J.M.G. Larkin (The Royal Marsden NHS Foundation Trust)H-Index: 14
Last. Laurence Albiges (Institut Gustave Roussy)H-Index: 61
view all 19 authors...
Background Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the efficacy of avelumab plus axitinib versus sunitinib in patients with treatment-naive advanced sRCC. Methods The randomized, open-label, multicenter, phase III JAVELIN Renal 101 trial (NCT02684006) enrolled patients with treatment-naive advanced RCC. Patients were randomized 1 : 1 to receive either avelumab plus axitinib or sunitinib fo...
#1K. Rzeniewicz (Francis Crick Institute)H-Index: 1
#2J.M.G. Larkin (The Royal Marsden NHS Foundation Trust)H-Index: 14
Last. Samra Turajlic (The Royal Marsden NHS Foundation Trust)H-Index: 30
view all 4 authors...
BACKGROUND Based on favourable outcomes in clinical trials, immune checkpoint inhibitors (ICIs), most notably programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitors, are now widely used across multiple cancer types. However, due to their strict inclusion and exclusion criteria, clinical studies often do not address challenges presented by non-trial populations. AREAS COVERED This review summarises available data on the efficacy and safety of ICIs in trial...
#1Helen Gogas (UoA: National and Kapodistrian University of Athens)H-Index: 62
#2Brigitte Dréno (University of Nantes)H-Index: 88
Last. A. Arance (University of Barcelona)H-Index: 6
view all 20 authors...
Background Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma. Patients and methods IMspire170 was an international, randomized, open-label, phase III study. Patients were randomized 1 : 1 to receive c...
#1Ahmad A. TarhiniH-Index: 53
#2Kabirraaj ToorH-Index: 7
Last. H.M. Johnson (BMS: Bristol-Myers Squibb)H-Index: 1
view all 14 authors...
Background Approved first-line treatments for patients with BRAF V600–mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; NIVO+IPI) and the BRAF/MEK inhibitors dabrafenib plus trametinib (DAB+TRAM), encorafenib plus binimetinib (ENCO+BINI), and vemurafenib plus cobimetinib (VEM+COBI). Results from prospective randomized clinical trials (RCTs) comparing these treatments have not yet been reported. ...
#9Rebecca Lee (University of Manchester)H-Index: 19
Background KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting individual pathway components is ineffective. Design The protein kinases RAF and SRC are validated therapeutic targets in KRA...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.